Plasminogen Plus rt-PA Improves Intraarterial Thrombolytic Therapy in Acute Ischemic Stroke
To improve the effectiveness of LIF, it is not reasonable to increase the local dose of u-PA or rt-PA in view of side effects that might be expected.
The proteolytic enzyme that is responsible for fibrinolysis is plasmin. Because all the fibrinolytic drugs are activators converting PG into plasmin, fibrinolysis might be improved to a lesser degree by increasing the dose of activators, but far more by adding its substrate: plasminogen.
KeywordsMiddle Cerebral Artery Acute Ischemic Stroke Tissue Plasminogen Activator Complete Recanalization Clot Volume
Unable to display preview. Download preview PDF.
- 2.Hacke W, Hirschberg M (1990) Thrombolytic therapy in acute ischemic stroke—an update. Stroke Int 1: 17–19Google Scholar
- 7.Zeumer H, Freitag HJ, Knospe V (1992) Intravascular thrombolysis in central nervous system cerebrovascular disease. Neuroimaging Clin North Am 2: 359–369Google Scholar
- 8.Zeumer H, Zanella FE (1993) Local intraarterial fibrinolysis in the vertebrobasilar and carotid territories. In: Valvanis A (ed) Interventional neuroradiology. Springer, Verlag, BerlinGoogle Scholar
- 10.Tilsner V, Witte G (1988) Effectiveness of intraarterial plasminogen application in combination with percutaneous transluminal angioplasty or catheter-assisted lysis in patients with chronical peripheral occlusive disease of the lower limbs. Hemostasis 18 (suppl 1): 139–156Google Scholar